Rethinking heart-lung support: We focus on the essential requirements of patients and their treating physicians in situations where extracorporeal support is critical. With our innovations and solutions, we redefine the field of Extracorporeal Life Support (ECLS and ECMO) –
full attention, strict focus, easy access.
full attention, strict focus, easy access.
Total raised: $6.81M
Founded date: 2013
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.04.2017 | - | $810K | - |
| 10.02.2016 | Series A | $6M | - |
Mentions in press and media 4
| Date | Title | Description |
| 25.07.2017 | Hemovent raises €2 million to bring its mini heart and lung support devices to market | German medtech startup Hemovent has just raised €2 million in an expansion of its Series A financing of €6 million in February 2016. Investors in the company include Seed Fonds Aachen, KfW-Bank, NRW-Bank, and MIG-Investmentfonds. According ... |
| 21.07.2017 | Hemovent Expands Series A Financing | Hemovent GmbH, an Aachen, Germany-based artificial lung platform developer, received an undisclosed funding as an extention of its Series A financing round. Backers included all existing investors as well as new investor 1st Capital Partner... |
| 24.04.2017 | Hemovent Receives Grant Totaling $810K from German Government | Hemovent GmbH, an Aachen, Germany-based venture backed medical device company, received a grant totaling $810k from the German Government. The company intends to use the funds accelerate development of its novel and portable artificial lung... |
| 10.02.2016 | Hemovent Closes $6M Series A Funding | Hemovent GmbH, an Aachen, Germany-based medical device company, closed a $6m Series A funding. The round was led by MIG Verwaltungs AG (Munich, Germany) with participation from WCTI Partners (Portland, Ore., USA); Seed Fond Aachen II (Aache... |